These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

829 related items for PubMed ID: 16292596

  • 1. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, Shmarov MM, Zhirnov OP, Varich NP, Ilyinskii PO, Shneider AM.
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [Abstract] [Full Text] [Related]

  • 2. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein.
    James CM, Abdad MY, Mansfield JP, Jacobsen HK, Vind AR, Stumbles PA, Bartlett EJ.
    Vaccine; 2007 Feb 26; 25(10):1856-67. PubMed ID: 17240000
    [Abstract] [Full Text] [Related]

  • 3. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M, Tao P, Li J, Zhou S, Guo D, Pan Z.
    J Virol Methods; 2008 Dec 26; 154(1-2):121-7. PubMed ID: 18789973
    [Abstract] [Full Text] [Related]

  • 4. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
    Ohba K, Yoshida S, Zahidunnabi Dewan M, Shimura H, Sakamaki N, Takeshita F, Yamamoto N, Okuda K.
    Vaccine; 2007 May 22; 25(21):4291-300. PubMed ID: 17403560
    [Abstract] [Full Text] [Related]

  • 5. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS, Seo YB, Lee JY, Im SJ, Seo SH, Song MS, Choi YK, Sung YC.
    Vaccine; 2011 Jul 26; 29(33):5481-7. PubMed ID: 21664216
    [Abstract] [Full Text] [Related]

  • 6. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus.
    Saha S, Yoshida S, Ohba K, Matsui K, Matsuda T, Takeshita F, Umeda K, Tamura Y, Okuda K, Klinman D, Xin KQ, Okuda K.
    Virology; 2006 Oct 10; 354(1):48-57. PubMed ID: 16945400
    [Abstract] [Full Text] [Related]

  • 7. Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.
    Thueng-in K, Maneewatch S, Srimanote P, Songserm T, Tapchaisri P, Sookrung N, Tongtawe P, Channarong S, Chaicumpa W.
    Vaccine; 2010 Sep 24; 28(41):6765-77. PubMed ID: 20688037
    [Abstract] [Full Text] [Related]

  • 8. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
    Wang W, Li R, Deng Y, Lu N, Chen H, Meng X, Wang W, Wang X, Yan K, Qi X, Zhang X, Xin W, Lu Z, Li X, Bian T, Gao Y, Tan W, Ruan L.
    Clin Vaccine Immunol; 2015 Jun 24; 22(6):618-30. PubMed ID: 25834017
    [Abstract] [Full Text] [Related]

  • 9. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
    Tao P, Luo M, Pan R, Ling D, Zhou S, Tien P, Pan Z.
    Antiviral Res; 2009 Mar 24; 81(3):253-60. PubMed ID: 19135483
    [Abstract] [Full Text] [Related]

  • 10. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
    Fu TM, Guan L, Friedman A, Schofield TL, Ulmer JB, Liu MA, Donnelly JJ.
    J Immunol; 1999 Apr 01; 162(7):4163-70. PubMed ID: 10201942
    [Abstract] [Full Text] [Related]

  • 11. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
    Du N, Li W, Li Y, Liu S, Sui Y, Qu Z, Wang Y, Du Y, Xu B.
    Vaccine; 2008 Jun 02; 26(23):2912-8. PubMed ID: 18448208
    [Abstract] [Full Text] [Related]

  • 12. Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses.
    Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL.
    Vaccine; 2009 Nov 05; 27(47):6512-21. PubMed ID: 19729082
    [Abstract] [Full Text] [Related]

  • 13. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E, Munster VJ, Spronken MI, Bestebroer TM, Baas C, Beyer WE, Rimmelzwaan GF, Osterhaus AD, Fouchier RA.
    J Virol; 2005 Oct 05; 79(19):12401-7. PubMed ID: 16160167
    [Abstract] [Full Text] [Related]

  • 14. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge.
    Breathnach CC, Clark HJ, Clark RC, Olsen CW, Townsend HG, Lunn DP.
    Vaccine; 2006 Feb 20; 24(8):1180-90. PubMed ID: 16194586
    [Abstract] [Full Text] [Related]

  • 15. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H, Peng X, Jiao H, Zhao D, Ouyang J.
    Microb Cell Fact; 2015 Aug 05; 14():111. PubMed ID: 26242406
    [Abstract] [Full Text] [Related]

  • 16. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W, Huang B, Wang X, Tan W, Ruan L.
    Virol Sin; 2019 Oct 05; 34(5):583-591. PubMed ID: 31240620
    [Abstract] [Full Text] [Related]

  • 17. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant.
    Zanvit P, Havlícková M, Tácner J, Novotná O, Jirkovská M, Cechová D, Julák J, Sterzl I, Prokesová L.
    Immunol Lett; 2008 Jan 29; 115(2):144-52. PubMed ID: 18160106
    [Abstract] [Full Text] [Related]

  • 18. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.
    Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.
    Virol J; 2012 Dec 29; 9():322. PubMed ID: 23272943
    [Abstract] [Full Text] [Related]

  • 19. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

  • 20. A live bivalent influenza vaccine based on a H9N2 virus strain.
    Wu R, Guan Y, Yang Z, Chen J, Wang H, Chen Q, Sui Z, Fang F, Chen Z.
    Vaccine; 2010 Jan 08; 28(3):673-80. PubMed ID: 19892041
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.